[Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia].
Obesity is the one of the fundamental problems in societies of the highly developed countries. In the Framingham study almost linear dependence between cardiovascular mortality and overweight was proven. Moreover, obesity often coexists with different illnesses, such as type 2 diabetes, myocardial ischaemia, essential hypertension, dyslipidemia, arteriosclerosis, renal insufficiency, degenerative changes of joints, cholelithiasis, or some neoplasms. Among methods of treatment of obesity the most known and safe is the low calories content diet. In pharmacotherapy of obesity two medications of new generation i.e. sibutramin and orlistat make up basis at present. The present study is concentrated onto Sibutramin, which acts in the central nervous system. Authors introduce mechanisms of action of the medicine, its participation in termogenesis as well as therapeutic effectiveness. Special attention is dedicated for clinical situations in which decrease of body mass is the key element of therapy, that is essential hypertension, diabetes and hyperlipidemia.
Rajzer
Marek
M
I Klinika Kardiologii Instytutu Kardiologii Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie.
Wojciechowska
Wiktoria
W
Kawecka-Jaszcz
Kalina
K
D000818:Animals; D001067:Appetite Depressants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003503:Cyclobutanes / Q000627:therapeutic use*; D019049:Developed Countries; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D009765:Obesity / Q000150:complications* / Q000188:drug therapy*
D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine